董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shao Lee Lin | 女 | President and Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2026-06-01 |
| Daniel Camardo | 男 | Director | 58 | 未披露 | 未持股 | 2026-06-01 |
| Pamela D. Garzone | 女 | Director | 71 | 6.94万美元 | 8.88 | 2026-06-01 |
| Pasha Sarraf | 男 | Chairman and Director | 56 | 8.81万美元 | 34.00 | 2026-06-01 |
| Viola Meehan | 女 | Director | -- | 未披露 | 未持股 | 2026-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Colin G. Sandercock | 男 | Senior Vice President, Intellectual Property | 69 | 59.92万美元 | 62.38 | 2026-06-01 |
| Shao Lee Lin | 女 | President and Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2026-06-01 |
| Sumita Ray | 女 | Chief Legal & Compliance Officer and Corporate Secretary | 52 | 未披露 | 未持股 | 2026-06-01 |
| Daniel G. Baker | 男 | Interim Chief Development Officer | 75 | 未披露 | 未持股 | 2026-06-01 |
| Michael Meluzio | 男 | Principal Accounting Officer and Vice President | 42 | 未披露 | 未持股 | 2026-06-01 |
董事简历
中英对照 | 中文 | 英文- Shao Lee Lin
-
Shao Lee Lin，Acelyrin，Inc创始人、首席执行官，自2020年7月起担任Acelyrin，Inc董事会成员。她自2021年1月起担任上市公司Surrozen公司的董事，并曾于2020年9月至2023年1月担任上市公司Third Harmonic Bio, Inc.的董事，并于2019年4月至2020年9月担任上市公司Principia Biopharma Inc.的董事。她也是湖森林学院董事会的董事。从2018年1月至2020年1月，林博士在生物制药公司Horizon Therapeutics Public Limited Company担任执行副总裁、研发主管和首席科学官。在此之前，她曾在生物技术公司艾伯维公司担任多个职位，包括公司官员级别的职位，最近负责治疗领域、卓越开发和国际开发，最初于2015年3月至2017年12月担任全球免疫学和肾脏开发副总裁。在加入艾伯维之前，林博士曾于2012年8月至2015年2月在吉利德科学公司担任炎症和呼吸发展副总裁，并于2004年4月至2012年8月在安进公司担任各种职责。林博士曾在洛克菲勒大学担任临床学者，并在康奈尔大学、加州大学洛杉矶分校、斯坦福大学和西北大学的医学院担任兼职教师。林博士在约翰·霍普金斯大学医学院获得了医学博士学位，这是美国国立卫生研究院资助的医学科学家培训项目的一部分，并在莱斯大学获得了化学工程和生物化学学士学位。
Shao Lee Lin,is Acelyrin, Inc Founder, Chief Executive Officer and a member of Acelyrin, Inc board of directors since July 2020. She currently serves as a director of Surrozen, Inc. since January 2021, which is a publicly-traded company, and previously served as a director of Third Harmonic Bio, Inc., a publicly traded company, from September 2020 to January 2023 and Principia Biopharma Inc., a publicly traded company, from April 2019 to September 2020. She is also a trustee of the board of Lake Forest College. From January 2018 to January 2020, Dr. Lin served as the Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon Therapeutics Public Limited Company, which is a biopharmaceutical company. Prior to that, she held multiple positions including at the corporate officer level within AbbVie Inc., which is a biotechnology company, most recently leading Therapeutic Areas, Development Excellence and International Development and initially as Vice President, Global Immunology and Renal Development from March 2015 to December 2017. Prior to AbbVie, Dr. Lin served as Vice President, Inflammation and Respiratory Development at Gilead Sciences Inc. from August 2012 to February 2015 and served in various roles of increasing responsibility at Amgen Inc. from April 2004 to August 2012. Dr. Lin has been faculty as a Clinical Scholar at The Rockefeller University and adjunct faculty at the medical schools of Cornell University, The University of California, Los Angeles (UCLA), Stanford University and Northwestern University. Dr. Lin received an M.D. and Ph.D. from The Johns Hopkins University School of Medicine as a part of the National Institutes of Health-sponsored medical scientist training program and a bachelor's degree in chemical engineering and biochemistry from Rice University. - Shao Lee Lin，Acelyrin，Inc创始人、首席执行官，自2020年7月起担任Acelyrin，Inc董事会成员。她自2021年1月起担任上市公司Surrozen公司的董事，并曾于2020年9月至2023年1月担任上市公司Third Harmonic Bio, Inc.的董事，并于2019年4月至2020年9月担任上市公司Principia Biopharma Inc.的董事。她也是湖森林学院董事会的董事。从2018年1月至2020年1月，林博士在生物制药公司Horizon Therapeutics Public Limited Company担任执行副总裁、研发主管和首席科学官。在此之前，她曾在生物技术公司艾伯维公司担任多个职位，包括公司官员级别的职位，最近负责治疗领域、卓越开发和国际开发，最初于2015年3月至2017年12月担任全球免疫学和肾脏开发副总裁。在加入艾伯维之前，林博士曾于2012年8月至2015年2月在吉利德科学公司担任炎症和呼吸发展副总裁，并于2004年4月至2012年8月在安进公司担任各种职责。林博士曾在洛克菲勒大学担任临床学者，并在康奈尔大学、加州大学洛杉矶分校、斯坦福大学和西北大学的医学院担任兼职教师。林博士在约翰·霍普金斯大学医学院获得了医学博士学位，这是美国国立卫生研究院资助的医学科学家培训项目的一部分，并在莱斯大学获得了化学工程和生物化学学士学位。
- Shao Lee Lin,is Acelyrin, Inc Founder, Chief Executive Officer and a member of Acelyrin, Inc board of directors since July 2020. She currently serves as a director of Surrozen, Inc. since January 2021, which is a publicly-traded company, and previously served as a director of Third Harmonic Bio, Inc., a publicly traded company, from September 2020 to January 2023 and Principia Biopharma Inc., a publicly traded company, from April 2019 to September 2020. She is also a trustee of the board of Lake Forest College. From January 2018 to January 2020, Dr. Lin served as the Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon Therapeutics Public Limited Company, which is a biopharmaceutical company. Prior to that, she held multiple positions including at the corporate officer level within AbbVie Inc., which is a biotechnology company, most recently leading Therapeutic Areas, Development Excellence and International Development and initially as Vice President, Global Immunology and Renal Development from March 2015 to December 2017. Prior to AbbVie, Dr. Lin served as Vice President, Inflammation and Respiratory Development at Gilead Sciences Inc. from August 2012 to February 2015 and served in various roles of increasing responsibility at Amgen Inc. from April 2004 to August 2012. Dr. Lin has been faculty as a Clinical Scholar at The Rockefeller University and adjunct faculty at the medical schools of Cornell University, The University of California, Los Angeles (UCLA), Stanford University and Northwestern University. Dr. Lin received an M.D. and Ph.D. from The Johns Hopkins University School of Medicine as a part of the National Institutes of Health-sponsored medical scientist training program and a bachelor's degree in chemical engineering and biochemistry from Rice University.
- Daniel Camardo
-
Daniel Camardo，2022年2月加入Athersys，担任Athersys, Inc.首席执行官。此前，卡马尔多曾在2020年8月至2022年2月期间担任全球生物技术公司Horizon Therapeutics plc的美国总裁和执行副总裁，负责管理罕见病和炎症业务部门，并在2015年9月至2020年8月期间担任集团副总裁。在加入Horizon Therapeutics之前，Camardo先生于2014年7月至2015年9月担任Clarus Therapeutics的销售和运营副总裁，该公司是一家专注于男性健康的初创公司。在加入Clarus Therapeutics之前，Camardo先生曾担任多个商业领导职务，包括2003年至2014年在Astellas Pharma US担任美国商业运营高级总监和市场情报与分析高级总监，该公司是日本全球制药公司Astellas Pharma Inc.的子公司。卡马尔多先生于2022年2月成为家乐氏管理学院（HCAK）的医疗保健兼职讲师，并在芝加哥社区健康委员会任职，该委员会是美国最大的志愿者健康中心，为低收入、无保险的成年人免费提供医疗服务。Camardo先生拥有罗切斯特大学的经济学和数学学士学位，以及家乐氏管理学院的工商管理硕士学位。
Daniel Camardo,joined Athersys in February 2022 as Athersys, Inc. Chief Executive Officer. Previously, Mr. Camardo served as the President, U.S., and the Executive Vice President of Horizon Therapeutics plc, a global biotechnology company, overseeing the Rare Disease and Inflammation Business Units from August 2020 to February 2022, and served as Group Vice President from September 2015 to August 2020. Before joining Horizon Therapeutics, Mr. Camardo was Vice President of Sales and Operations at Clarus Therapeutics, a start-up company focused on men's health, from July 2014 to September 2015. Prior to joining Clarus Therapeutics, Mr. Camardo held various commercial leadership roles, including Senior Director, U.S. Commercial Operations and Senior Director, Market Intelligence and Analytics from 2003 to 2014 at Astellas Pharma US, an affiliate of Astellas Pharma Inc., a Japanese global pharmaceutical company. Mr. Camardo became an Adjunct Lecturer in Healthcare at Kellogg School of Management (HCAK), in February 2022 and serves on the Board of CommunityHealth, the largest volunteer-based health center in the nation providing health care at no charge to low-income, uninsured adults, in Chicago. Mr. Camardo holds a Bachelor of Arts degree in Economics and Mathematics from the University of Rochester and a Masters of Business Administration from Kellogg School of Management. - Daniel Camardo，2022年2月加入Athersys，担任Athersys, Inc.首席执行官。此前，卡马尔多曾在2020年8月至2022年2月期间担任全球生物技术公司Horizon Therapeutics plc的美国总裁和执行副总裁，负责管理罕见病和炎症业务部门，并在2015年9月至2020年8月期间担任集团副总裁。在加入Horizon Therapeutics之前，Camardo先生于2014年7月至2015年9月担任Clarus Therapeutics的销售和运营副总裁，该公司是一家专注于男性健康的初创公司。在加入Clarus Therapeutics之前，Camardo先生曾担任多个商业领导职务，包括2003年至2014年在Astellas Pharma US担任美国商业运营高级总监和市场情报与分析高级总监，该公司是日本全球制药公司Astellas Pharma Inc.的子公司。卡马尔多先生于2022年2月成为家乐氏管理学院（HCAK）的医疗保健兼职讲师，并在芝加哥社区健康委员会任职，该委员会是美国最大的志愿者健康中心，为低收入、无保险的成年人免费提供医疗服务。Camardo先生拥有罗切斯特大学的经济学和数学学士学位，以及家乐氏管理学院的工商管理硕士学位。
- Daniel Camardo,joined Athersys in February 2022 as Athersys, Inc. Chief Executive Officer. Previously, Mr. Camardo served as the President, U.S., and the Executive Vice President of Horizon Therapeutics plc, a global biotechnology company, overseeing the Rare Disease and Inflammation Business Units from August 2020 to February 2022, and served as Group Vice President from September 2015 to August 2020. Before joining Horizon Therapeutics, Mr. Camardo was Vice President of Sales and Operations at Clarus Therapeutics, a start-up company focused on men's health, from July 2014 to September 2015. Prior to joining Clarus Therapeutics, Mr. Camardo held various commercial leadership roles, including Senior Director, U.S. Commercial Operations and Senior Director, Market Intelligence and Analytics from 2003 to 2014 at Astellas Pharma US, an affiliate of Astellas Pharma Inc., a Japanese global pharmaceutical company. Mr. Camardo became an Adjunct Lecturer in Healthcare at Kellogg School of Management (HCAK), in February 2022 and serves on the Board of CommunityHealth, the largest volunteer-based health center in the nation providing health care at no charge to low-income, uninsured adults, in Chicago. Mr. Camardo holds a Bachelor of Arts degree in Economics and Mathematics from the University of Rochester and a Masters of Business Administration from Kellogg School of Management.
- Pamela D. Garzone
-
Pamela Garzone，自2021年9月起担任Anixa Biosciences, Inc.的首席开发官，该公司专注于肿瘤学和传染病。在加入Anixa之前，Garzone博士曾于2019年5月至2021年5月在Scripps研究所的一个部门Calibr担任首席医疗官。从2009年5月到2019年5月，Garzone博士担任副总裁，集团资产团队负责人，在辉瑞公司专注于早期肿瘤临床研究。Garzone博士获得了普渡大学的药学学士学位和匹兹堡大学的药学实践硕士学位。Garzone博士在匹兹堡大学获得临床科学博士学位。
Pamela D. Garzone joined board of directors in April 2023. Dr. Garzone has served as the Chief Development Officer at Anixa Biosciences, Inc., a company focused on oncology and infectio diseases, since September 2021. Prior to joining Anixa, Dr. Garzone served as the Chief Medical Officer at Calibr, a division of the Scripps Research Institute from May 2019 to May 2021. From May 2009 through May 2019, Dr. Garzone served as the Vice President, Group Asset Team Lead focused on early oncology clinical research at Pfizer Inc. Dr. Garzone earned a B.S. degree in pharmacy from Purdue University and an M.S. in pharmacy practice from the University of Pittsburgh. Dr. Garzone received her Ph.D. in clinical science from the University of Pittsburgh. - Pamela Garzone，自2021年9月起担任Anixa Biosciences, Inc.的首席开发官，该公司专注于肿瘤学和传染病。在加入Anixa之前，Garzone博士曾于2019年5月至2021年5月在Scripps研究所的一个部门Calibr担任首席医疗官。从2009年5月到2019年5月，Garzone博士担任副总裁，集团资产团队负责人，在辉瑞公司专注于早期肿瘤临床研究。Garzone博士获得了普渡大学的药学学士学位和匹兹堡大学的药学实践硕士学位。Garzone博士在匹兹堡大学获得临床科学博士学位。
- Pamela D. Garzone joined board of directors in April 2023. Dr. Garzone has served as the Chief Development Officer at Anixa Biosciences, Inc., a company focused on oncology and infectio diseases, since September 2021. Prior to joining Anixa, Dr. Garzone served as the Chief Medical Officer at Calibr, a division of the Scripps Research Institute from May 2019 to May 2021. From May 2009 through May 2019, Dr. Garzone served as the Vice President, Group Asset Team Lead focused on early oncology clinical research at Pfizer Inc. Dr. Garzone earned a B.S. degree in pharmacy from Purdue University and an M.S. in pharmacy practice from the University of Pittsburgh. Dr. Garzone received her Ph.D. in clinical science from the University of Pittsburgh.
- Pasha Sarraf
-
Pasha Sarraf，自2023年起担任战略咨询公司Upupa Advisory的负责人。Sarraf博士此前曾在2021年至2023年期间担任生物技术公司Matterhorn Biosciences的首席执行官和执行董事会成员，在那里他建立了一个支持团队，并扩大了科学努力，以证明他们基于T细胞受体的平台的价值。在加入Matterhorn Biosciences之前，Sarraf博士曾于2020年至2021年担任风险投资公司Flagship Pioneering的运营合伙人。在那里，他带领旗舰Pioneering的投资组合公司的一个团队在帕金森病中发现了新的基因回路，启动了一个创新靶点的药物发现计划，该计划后来获得了GSK plc的许可。在加入Flagship Pioneering之前，Sarraf博士曾在Leerink Partners（前身为SVB Leerink）担任高级华尔街分析师和董事总经理。在此之前，Sarraf博士于2008年加入麦肯锡公司，担任过各种职务，包括从2015年到2018年担任生命科学实践的合伙人，在那里他专注于战略、勤奋和预测。Sarraf博士是生物技术公司PolarityBio和Praesidia Biotherapeutics的董事会成员，并担任董事长。Sarraf博士在哈佛医学院获得了医学博士学位，并在麻省总医院和美国国立卫生研究院接受了内科和风湿病学方面的培训，专注于血管炎、硬皮病和遗传炎症性疾病。
Pasha Sarraf joined board of directors in March 2025 and was appointed as Chairman in June 2025. Dr. Sarraf has served as Principal at Upupa Advisory, a strategic advisory firm, since 2023. Dr. Sarraf previoly served as the Chief Executive Officer and executive board member of Matterhorn Biosciences, a biotechnology company, from 2021 to 2023, where he built a supportive team and scaled the scientific effort to demonstrate the value of their T cell receptors based platform. Prior to joining Matterhorn Biosciences, Dr. Sarraf served as an Operating Partner of Flagship Pioneering, a venture capital company, from 2020 to 2021. There, he led a team at a portfolio company of Flagship Pioneering who discovered novel genetic circuits in Parkinson's Disease, initiating a drug discovery program for an innovative target that was later licensed by GSK plc. Prior to joining Flagship Pioneering, Dr. Sarraf served as Senior Wall Street Analyst and Managing Director at Leerink Partners, formerly SVB Leerink. Prior to that, Dr. Sarraf joined McKinsey & Company in 2008 and served in vario roles, including as Partner in the life sciences practice from 2015 through 2018, where he focused on strategy, diligence and forecasting. Dr. Sarraf is a member of the boards of directors of biotechnology companies PolarityBio and Praesidia Biotherapeutics, where he serves as Chairman. Dr. Sarraf obtained his M.D. and Ph.D. at Harvard Medical School and trained in internal medicine and rheumatology at Massachetts General Hospital and National Institutes of Health, focing on vasculitis, scleroderma and genetic inflammatory disorders. Dr. Sarraf has authored over 50 publications and multiple patents for novel therapies and molecular targets. - Pasha Sarraf，自2023年起担任战略咨询公司Upupa Advisory的负责人。Sarraf博士此前曾在2021年至2023年期间担任生物技术公司Matterhorn Biosciences的首席执行官和执行董事会成员，在那里他建立了一个支持团队，并扩大了科学努力，以证明他们基于T细胞受体的平台的价值。在加入Matterhorn Biosciences之前，Sarraf博士曾于2020年至2021年担任风险投资公司Flagship Pioneering的运营合伙人。在那里，他带领旗舰Pioneering的投资组合公司的一个团队在帕金森病中发现了新的基因回路，启动了一个创新靶点的药物发现计划，该计划后来获得了GSK plc的许可。在加入Flagship Pioneering之前，Sarraf博士曾在Leerink Partners（前身为SVB Leerink）担任高级华尔街分析师和董事总经理。在此之前，Sarraf博士于2008年加入麦肯锡公司，担任过各种职务，包括从2015年到2018年担任生命科学实践的合伙人，在那里他专注于战略、勤奋和预测。Sarraf博士是生物技术公司PolarityBio和Praesidia Biotherapeutics的董事会成员，并担任董事长。Sarraf博士在哈佛医学院获得了医学博士学位，并在麻省总医院和美国国立卫生研究院接受了内科和风湿病学方面的培训，专注于血管炎、硬皮病和遗传炎症性疾病。
- Pasha Sarraf joined board of directors in March 2025 and was appointed as Chairman in June 2025. Dr. Sarraf has served as Principal at Upupa Advisory, a strategic advisory firm, since 2023. Dr. Sarraf previoly served as the Chief Executive Officer and executive board member of Matterhorn Biosciences, a biotechnology company, from 2021 to 2023, where he built a supportive team and scaled the scientific effort to demonstrate the value of their T cell receptors based platform. Prior to joining Matterhorn Biosciences, Dr. Sarraf served as an Operating Partner of Flagship Pioneering, a venture capital company, from 2020 to 2021. There, he led a team at a portfolio company of Flagship Pioneering who discovered novel genetic circuits in Parkinson's Disease, initiating a drug discovery program for an innovative target that was later licensed by GSK plc. Prior to joining Flagship Pioneering, Dr. Sarraf served as Senior Wall Street Analyst and Managing Director at Leerink Partners, formerly SVB Leerink. Prior to that, Dr. Sarraf joined McKinsey & Company in 2008 and served in vario roles, including as Partner in the life sciences practice from 2015 through 2018, where he focused on strategy, diligence and forecasting. Dr. Sarraf is a member of the boards of directors of biotechnology companies PolarityBio and Praesidia Biotherapeutics, where he serves as Chairman. Dr. Sarraf obtained his M.D. and Ph.D. at Harvard Medical School and trained in internal medicine and rheumatology at Massachetts General Hospital and National Institutes of Health, focing on vasculitis, scleroderma and genetic inflammatory disorders. Dr. Sarraf has authored over 50 publications and multiple patents for novel therapies and molecular targets.
- Viola Meehan
-
Viola Meehan于2020年1月至2023年1月退休期间担任Vanqua Bio，Inc. 首席财务官。2009年4月至2019年11月，Meehan女士在艾伯维公司担任研发财务和运营集团副总裁。Meehan女士于1992年加入雅培，并通过支持商业、研发、运营、业务发展和其他公司职能的各种财务领导角色取得进展，直到2009年加入艾伯维公司。米汉女士的公共会计职业生涯始于普华永道会计师事务所。米汉女士在宾夕法尼亚大学沃顿商学院获得会计学学士学位，在芝加哥大学获得金融MBA学位。
Viola Meehan served as Chief Financial Officer of Vanqua Bio, Inc. from January 2020 to her retirement in January 2023. From April 2009 to November 2019, Ms. Meehan served as Vice President, Research & Development Finance & Operations group at AbbVie Inc. Ms. Meehan joined Abbott in 1992 and progressed through a wide variety of finance leadership roles supporting Commercial, R&D, Operations, Business Development and other Corporate functions until joining AbbVie Inc. in 2009. Ms. Meehan began her career in public accounting at Price Waterhouse Coopers LLP. Ms. Meehan earned her Bachelor's degree in Accounting from the Wharton School of Business at the University of Pennsylvania and her MBA in Finance from the University of Chicago. - Viola Meehan于2020年1月至2023年1月退休期间担任Vanqua Bio，Inc. 首席财务官。2009年4月至2019年11月，Meehan女士在艾伯维公司担任研发财务和运营集团副总裁。Meehan女士于1992年加入雅培，并通过支持商业、研发、运营、业务发展和其他公司职能的各种财务领导角色取得进展，直到2009年加入艾伯维公司。米汉女士的公共会计职业生涯始于普华永道会计师事务所。米汉女士在宾夕法尼亚大学沃顿商学院获得会计学学士学位，在芝加哥大学获得金融MBA学位。
- Viola Meehan served as Chief Financial Officer of Vanqua Bio, Inc. from January 2020 to her retirement in January 2023. From April 2009 to November 2019, Ms. Meehan served as Vice President, Research & Development Finance & Operations group at AbbVie Inc. Ms. Meehan joined Abbott in 1992 and progressed through a wide variety of finance leadership roles supporting Commercial, R&D, Operations, Business Development and other Corporate functions until joining AbbVie Inc. in 2009. Ms. Meehan began her career in public accounting at Price Waterhouse Coopers LLP. Ms. Meehan earned her Bachelor's degree in Accounting from the Wharton School of Business at the University of Pennsylvania and her MBA in Finance from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Colin G. Sandercock
ColinG.Sandercock自2017年12月4日起担任我们的高级副总裁，总法律顾问兼秘书。加入Cue Biopharma公司之前，他曾担任Perkins Coie LLP的合伙人（2010年7月以来），从事专利诉讼、采购、国内外专利组合的管理和执行、许可纠纷、商标纠纷，以及与侵权、有效性和运营自由有关的意见。Sandercock先生拥有摩拉维亚学院（Moravian College）的学士学位，宾夕法尼亚大学（University of Pennsylvania）的硕士学位和哥伦布法学院（Columbus School of Law）天主教大学（Catholic University）的法学博士学位。
Colin G. Sandercock has been Senior Vice President, General Counsel and Secretary since December 2017. Prior to joining Cue Biopharma, he was a partner at Perkins Coie LLP from July 2010 to December 2017, practicing in the areas of patent litigation, procurement, management and enforcement of domestic and foreign patent portfolio, licensing disputes, trademark disputes, and opinions relating to infringement, validity and freedom to operate. Mr. Sandercock holds a B.S. in Chemistry and Mathematics from Moravian College, a Materials Science & Engineering (M.S.E.) degree in Chemical and Biochemical Engineering from the University of Pennsylvania and a J.D. from Catholic University, Columb School of Law.- ColinG.Sandercock自2017年12月4日起担任我们的高级副总裁，总法律顾问兼秘书。加入Cue Biopharma公司之前，他曾担任Perkins Coie LLP的合伙人（2010年7月以来），从事专利诉讼、采购、国内外专利组合的管理和执行、许可纠纷、商标纠纷，以及与侵权、有效性和运营自由有关的意见。Sandercock先生拥有摩拉维亚学院（Moravian College）的学士学位，宾夕法尼亚大学（University of Pennsylvania）的硕士学位和哥伦布法学院（Columbus School of Law）天主教大学（Catholic University）的法学博士学位。
- Colin G. Sandercock has been Senior Vice President, General Counsel and Secretary since December 2017. Prior to joining Cue Biopharma, he was a partner at Perkins Coie LLP from July 2010 to December 2017, practicing in the areas of patent litigation, procurement, management and enforcement of domestic and foreign patent portfolio, licensing disputes, trademark disputes, and opinions relating to infringement, validity and freedom to operate. Mr. Sandercock holds a B.S. in Chemistry and Mathematics from Moravian College, a Materials Science & Engineering (M.S.E.) degree in Chemical and Biochemical Engineering from the University of Pennsylvania and a J.D. from Catholic University, Columb School of Law.
- Shao Lee Lin
Shao Lee Lin，Acelyrin，Inc创始人、首席执行官，自2020年7月起担任Acelyrin，Inc董事会成员。她自2021年1月起担任上市公司Surrozen公司的董事，并曾于2020年9月至2023年1月担任上市公司Third Harmonic Bio, Inc.的董事，并于2019年4月至2020年9月担任上市公司Principia Biopharma Inc.的董事。她也是湖森林学院董事会的董事。从2018年1月至2020年1月，林博士在生物制药公司Horizon Therapeutics Public Limited Company担任执行副总裁、研发主管和首席科学官。在此之前，她曾在生物技术公司艾伯维公司担任多个职位，包括公司官员级别的职位，最近负责治疗领域、卓越开发和国际开发，最初于2015年3月至2017年12月担任全球免疫学和肾脏开发副总裁。在加入艾伯维之前，林博士曾于2012年8月至2015年2月在吉利德科学公司担任炎症和呼吸发展副总裁，并于2004年4月至2012年8月在安进公司担任各种职责。林博士曾在洛克菲勒大学担任临床学者，并在康奈尔大学、加州大学洛杉矶分校、斯坦福大学和西北大学的医学院担任兼职教师。林博士在约翰·霍普金斯大学医学院获得了医学博士学位，这是美国国立卫生研究院资助的医学科学家培训项目的一部分，并在莱斯大学获得了化学工程和生物化学学士学位。
Shao Lee Lin,is Acelyrin, Inc Founder, Chief Executive Officer and a member of Acelyrin, Inc board of directors since July 2020. She currently serves as a director of Surrozen, Inc. since January 2021, which is a publicly-traded company, and previously served as a director of Third Harmonic Bio, Inc., a publicly traded company, from September 2020 to January 2023 and Principia Biopharma Inc., a publicly traded company, from April 2019 to September 2020. She is also a trustee of the board of Lake Forest College. From January 2018 to January 2020, Dr. Lin served as the Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon Therapeutics Public Limited Company, which is a biopharmaceutical company. Prior to that, she held multiple positions including at the corporate officer level within AbbVie Inc., which is a biotechnology company, most recently leading Therapeutic Areas, Development Excellence and International Development and initially as Vice President, Global Immunology and Renal Development from March 2015 to December 2017. Prior to AbbVie, Dr. Lin served as Vice President, Inflammation and Respiratory Development at Gilead Sciences Inc. from August 2012 to February 2015 and served in various roles of increasing responsibility at Amgen Inc. from April 2004 to August 2012. Dr. Lin has been faculty as a Clinical Scholar at The Rockefeller University and adjunct faculty at the medical schools of Cornell University, The University of California, Los Angeles (UCLA), Stanford University and Northwestern University. Dr. Lin received an M.D. and Ph.D. from The Johns Hopkins University School of Medicine as a part of the National Institutes of Health-sponsored medical scientist training program and a bachelor's degree in chemical engineering and biochemistry from Rice University.- Shao Lee Lin，Acelyrin，Inc创始人、首席执行官，自2020年7月起担任Acelyrin，Inc董事会成员。她自2021年1月起担任上市公司Surrozen公司的董事，并曾于2020年9月至2023年1月担任上市公司Third Harmonic Bio, Inc.的董事，并于2019年4月至2020年9月担任上市公司Principia Biopharma Inc.的董事。她也是湖森林学院董事会的董事。从2018年1月至2020年1月，林博士在生物制药公司Horizon Therapeutics Public Limited Company担任执行副总裁、研发主管和首席科学官。在此之前，她曾在生物技术公司艾伯维公司担任多个职位，包括公司官员级别的职位，最近负责治疗领域、卓越开发和国际开发，最初于2015年3月至2017年12月担任全球免疫学和肾脏开发副总裁。在加入艾伯维之前，林博士曾于2012年8月至2015年2月在吉利德科学公司担任炎症和呼吸发展副总裁，并于2004年4月至2012年8月在安进公司担任各种职责。林博士曾在洛克菲勒大学担任临床学者，并在康奈尔大学、加州大学洛杉矶分校、斯坦福大学和西北大学的医学院担任兼职教师。林博士在约翰·霍普金斯大学医学院获得了医学博士学位，这是美国国立卫生研究院资助的医学科学家培训项目的一部分，并在莱斯大学获得了化学工程和生物化学学士学位。
- Shao Lee Lin,is Acelyrin, Inc Founder, Chief Executive Officer and a member of Acelyrin, Inc board of directors since July 2020. She currently serves as a director of Surrozen, Inc. since January 2021, which is a publicly-traded company, and previously served as a director of Third Harmonic Bio, Inc., a publicly traded company, from September 2020 to January 2023 and Principia Biopharma Inc., a publicly traded company, from April 2019 to September 2020. She is also a trustee of the board of Lake Forest College. From January 2018 to January 2020, Dr. Lin served as the Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon Therapeutics Public Limited Company, which is a biopharmaceutical company. Prior to that, she held multiple positions including at the corporate officer level within AbbVie Inc., which is a biotechnology company, most recently leading Therapeutic Areas, Development Excellence and International Development and initially as Vice President, Global Immunology and Renal Development from March 2015 to December 2017. Prior to AbbVie, Dr. Lin served as Vice President, Inflammation and Respiratory Development at Gilead Sciences Inc. from August 2012 to February 2015 and served in various roles of increasing responsibility at Amgen Inc. from April 2004 to August 2012. Dr. Lin has been faculty as a Clinical Scholar at The Rockefeller University and adjunct faculty at the medical schools of Cornell University, The University of California, Los Angeles (UCLA), Stanford University and Northwestern University. Dr. Lin received an M.D. and Ph.D. from The Johns Hopkins University School of Medicine as a part of the National Institutes of Health-sponsored medical scientist training program and a bachelor's degree in chemical engineering and biochemistry from Rice University.
- Sumita Ray
Sumita Ray，自2021年6月起担任董事会成员。Ray女士目前在上市生物技术公司Vaxxinity（纳斯达克：VAXX）担任首席法律、合规与行政官兼公司秘书，她自2023年10月起担任该职位。在此之前，Ray女士曾在Instil Bio, Inc.（纳斯达克：TIL）担任首席法律、合规与行政官兼公司秘书一职，该公司是一家上市生物技术公司，她曾于2022年4月至2023年6月担任该职位。自2015年11月成立以来，Ray女士还是生命科学公司咨询公司FifthRay Consulting，LLC的主要和唯一成员。此前，从2017年9月至2022年4月，她担任首席法律和行政官，负责监督上市生物技术公司Calithera Biosciences, Inc.（纳斯达克：CALA）的法律、合规、人力资源、IT和设施职能。在加入Calithera之前，她曾担任Pharmacyclics, Inc.（纳斯达克：PCYC）的首席合规官和副总法律顾问、医疗保健和监管法律主管，该公司于2015年5月被艾伯维公司（纽约证券交易所代码：ABBV）收购，在那里她支持该公司在2013年4月至2015年11月期间通过Imbruvica在多个适应症的全球批准和推出。在此之前，Ray女士曾担任Elan Pharmaceuticals生物神经病学和监管法律小组负责人、Genentech，Inc.的公司法律顾问、商法小组以及阿斯利康（纳斯达克：AZN）的公司法律顾问。Ray女士还担任BioTrillion的顾问委员会成员，这是一家开发用于疾病检测的数字生物标志物的健康科技初创公司。Ray女士的职业生涯始于Montgomery，McCracken，Walker and Rhoads LLP的医药和产品责任诉讼律师。Ray女士拥有天普大学法学院法学博士学位和亚利桑那大学微生物学学士学位。她在FDA监管法、全球医疗保健法和合规、品牌支持、产品发布、合作和联盟方面拥有20多年的专业知识。
Sumita Ray has been in the biotech industry for over 25 years and has held positions as Chief Legal & Compliance Officer and Corporate Secretary for over a decade at various publicly traded companies. Most recently she served as Chief Legal, Compliance & Administrative Officer and Corporate Secretary at Vaxxinity (Nasdaq: VAXX), a formerly public biotechnology company from October 2023 through March 2025. Prior to that, Ms. Ray held the position of Chief Legal, Compliance & Administrative Officer and Corporate Secretary at the public biotechnology companies of Instil Bio, Inc. (Nasdaq: TIL) from April 2022 to June 2023, and Calithera BioSciences, Inc. (Nasdaq: CALA) from May 2017 to May 2022. Ms. Ray currently serves on the Board of Directors of Biomea Fusion, Inc.(Nasdaq: BMEA) to which she was appointed in July 2021.- Sumita Ray，自2021年6月起担任董事会成员。Ray女士目前在上市生物技术公司Vaxxinity（纳斯达克：VAXX）担任首席法律、合规与行政官兼公司秘书，她自2023年10月起担任该职位。在此之前，Ray女士曾在Instil Bio, Inc.（纳斯达克：TIL）担任首席法律、合规与行政官兼公司秘书一职，该公司是一家上市生物技术公司，她曾于2022年4月至2023年6月担任该职位。自2015年11月成立以来，Ray女士还是生命科学公司咨询公司FifthRay Consulting，LLC的主要和唯一成员。此前，从2017年9月至2022年4月，她担任首席法律和行政官，负责监督上市生物技术公司Calithera Biosciences, Inc.（纳斯达克：CALA）的法律、合规、人力资源、IT和设施职能。在加入Calithera之前，她曾担任Pharmacyclics, Inc.（纳斯达克：PCYC）的首席合规官和副总法律顾问、医疗保健和监管法律主管，该公司于2015年5月被艾伯维公司（纽约证券交易所代码：ABBV）收购，在那里她支持该公司在2013年4月至2015年11月期间通过Imbruvica在多个适应症的全球批准和推出。在此之前，Ray女士曾担任Elan Pharmaceuticals生物神经病学和监管法律小组负责人、Genentech，Inc.的公司法律顾问、商法小组以及阿斯利康（纳斯达克：AZN）的公司法律顾问。Ray女士还担任BioTrillion的顾问委员会成员，这是一家开发用于疾病检测的数字生物标志物的健康科技初创公司。Ray女士的职业生涯始于Montgomery，McCracken，Walker and Rhoads LLP的医药和产品责任诉讼律师。Ray女士拥有天普大学法学院法学博士学位和亚利桑那大学微生物学学士学位。她在FDA监管法、全球医疗保健法和合规、品牌支持、产品发布、合作和联盟方面拥有20多年的专业知识。
- Sumita Ray has been in the biotech industry for over 25 years and has held positions as Chief Legal & Compliance Officer and Corporate Secretary for over a decade at various publicly traded companies. Most recently she served as Chief Legal, Compliance & Administrative Officer and Corporate Secretary at Vaxxinity (Nasdaq: VAXX), a formerly public biotechnology company from October 2023 through March 2025. Prior to that, Ms. Ray held the position of Chief Legal, Compliance & Administrative Officer and Corporate Secretary at the public biotechnology companies of Instil Bio, Inc. (Nasdaq: TIL) from April 2022 to June 2023, and Calithera BioSciences, Inc. (Nasdaq: CALA) from May 2017 to May 2022. Ms. Ray currently serves on the Board of Directors of Biomea Fusion, Inc.(Nasdaq: BMEA) to which she was appointed in July 2021.
- Daniel G. Baker
Daniel G. Baker，在制药行业拥有超过20年的药物开发经验。贝克博士是生物技术公司Kira Therapeutics的创始人，自2019年起担任该公司的首席执行官。他还曾在2022年4月至2024年10月期间担任上市生物技术公司Galapagos NV的董事会执行董事。2000年至2019年，他在强生的Janssen/Centocor部门担任免疫学研发副总裁，该部门现在是强生创新药的一部分，他的职责包括Remicade、Simponi和Stelara的临床开发，以及其他主要的临床药物项目。他对多个疾病领域的众多1至3期临床试验的监督和监督导致在美国、欧洲和日本获得超过15项监管批准。2015年，贝克博士担任疾病领域Stronghold Leader的角色，负责风湿病产品的2期和3期临床试验开发计划以及风湿病和免疫学的整体组合战略。贝克博士在宾夕法尼亚大学获得医学博士学位。他在宾夕法尼亚州立健康Milton S. Hershey医疗中心完成了住院医师实习，并在宾夕法尼亚大学完成了风湿病学和免疫学研究金，随后在麻省总医院完成了风湿病学研究奖学金。
Daniel G. Baker has been Interim Chief Development Officer since November 2024. Dr. Baker has over 20 years of drug development experience in the pharmaceutical industry. Dr. Baker is the founder of Kira Therapeutics, a biotechnology company, where he has served as Chief Executive Officer since 2019. He also served as an Executive Director on the board of Galapagos NV, a publicly traded biotechnology company, from April 2022 until October 2024. From 2000 to 2019, he served as Vice President, Immunology R&D at Johnson & Johnson's Janssen/Centocor division, which is now part of Johnson & Johnson Innovative Medicine, where his responsibilities included clinical development of Remicade, Simponi and Stelara, as ll as other major clinical drug programs. His supervision and oversight of numero Phase 1 to 3 clinical trials in multiple disease areas led to more than 15 regulatory approvals in the U.S., Europe and Japan. In 2015, Dr. Baker assumed the role of Disease Area Stronghold Leader, where he was responsible for Phase 2 and 3 clinical trial development plans for rheumatology products and the overall portfolio strategy in rheumatology and immunology.- Daniel G. Baker，在制药行业拥有超过20年的药物开发经验。贝克博士是生物技术公司Kira Therapeutics的创始人，自2019年起担任该公司的首席执行官。他还曾在2022年4月至2024年10月期间担任上市生物技术公司Galapagos NV的董事会执行董事。2000年至2019年，他在强生的Janssen/Centocor部门担任免疫学研发副总裁，该部门现在是强生创新药的一部分，他的职责包括Remicade、Simponi和Stelara的临床开发，以及其他主要的临床药物项目。他对多个疾病领域的众多1至3期临床试验的监督和监督导致在美国、欧洲和日本获得超过15项监管批准。2015年，贝克博士担任疾病领域Stronghold Leader的角色，负责风湿病产品的2期和3期临床试验开发计划以及风湿病和免疫学的整体组合战略。贝克博士在宾夕法尼亚大学获得医学博士学位。他在宾夕法尼亚州立健康Milton S. Hershey医疗中心完成了住院医师实习，并在宾夕法尼亚大学完成了风湿病学和免疫学研究金，随后在麻省总医院完成了风湿病学研究奖学金。
- Daniel G. Baker has been Interim Chief Development Officer since November 2024. Dr. Baker has over 20 years of drug development experience in the pharmaceutical industry. Dr. Baker is the founder of Kira Therapeutics, a biotechnology company, where he has served as Chief Executive Officer since 2019. He also served as an Executive Director on the board of Galapagos NV, a publicly traded biotechnology company, from April 2022 until October 2024. From 2000 to 2019, he served as Vice President, Immunology R&D at Johnson & Johnson's Janssen/Centocor division, which is now part of Johnson & Johnson Innovative Medicine, where his responsibilities included clinical development of Remicade, Simponi and Stelara, as ll as other major clinical drug programs. His supervision and oversight of numero Phase 1 to 3 clinical trials in multiple disease areas led to more than 15 regulatory approvals in the U.S., Europe and Japan. In 2015, Dr. Baker assumed the role of Disease Area Stronghold Leader, where he was responsible for Phase 2 and 3 clinical trial development plans for rheumatology products and the overall portfolio strategy in rheumatology and immunology.
- Michael Meluzio
Michael Meluzio自2026年1月起担任公司财务副总裁，并于2024年1月至2026年1月担任公司公司财务总监。在加入公司之前，Meluzio先生于2022年3月至2024年1月在Omega Therapeutics担任公司控制人，并于2021年3月至2022年3月在Kiora制药，Inc.担任公司控制人。在此之前，Meluzio先生曾在武田制药公司、Shire（后被武田收购）、Green Key Resources和MHW，Ltd.的财务部门担任过多个职务。Meluzio先生的职业生涯始于普华永道会计师事务所，是纽约州的一名注册会计师。Meluzio先生拥有阿德尔菲大学会计学工商管理学士学位。
Michael Meluzio has served as the Company's VP of Finance since January 2026 and as the Company's Corporate Controller from January 2024 to January 2026. Prior to joining the Company, Mr. Meluzio served as Corporate Controller at Omega Therapeutics from March 2022 to January 2024 and at Kiora Pharmaceuticals, Inc. from March 2021 to March 2022. Prior to that, Mr. Meluzio held various roles in the finance departments at Takeda Pharmaceutical Company, Shire (subsequently acquired by Takeda), Green Key Resources and MHW, Ltd. Mr. Meluzio began his career at PricewaterhouseCoopers LLP and is a certified public accountant in the state of New York. Mr. Meluzio holds a Bachelor of Business Administration in Accounting from Adelphi University.- Michael Meluzio自2026年1月起担任公司财务副总裁，并于2024年1月至2026年1月担任公司公司财务总监。在加入公司之前，Meluzio先生于2022年3月至2024年1月在Omega Therapeutics担任公司控制人，并于2021年3月至2022年3月在Kiora制药，Inc.担任公司控制人。在此之前，Meluzio先生曾在武田制药公司、Shire（后被武田收购）、Green Key Resources和MHW，Ltd.的财务部门担任过多个职务。Meluzio先生的职业生涯始于普华永道会计师事务所，是纽约州的一名注册会计师。Meluzio先生拥有阿德尔菲大学会计学工商管理学士学位。
- Michael Meluzio has served as the Company's VP of Finance since January 2026 and as the Company's Corporate Controller from January 2024 to January 2026. Prior to joining the Company, Mr. Meluzio served as Corporate Controller at Omega Therapeutics from March 2022 to January 2024 and at Kiora Pharmaceuticals, Inc. from March 2021 to March 2022. Prior to that, Mr. Meluzio held various roles in the finance departments at Takeda Pharmaceutical Company, Shire (subsequently acquired by Takeda), Green Key Resources and MHW, Ltd. Mr. Meluzio began his career at PricewaterhouseCoopers LLP and is a certified public accountant in the state of New York. Mr. Meluzio holds a Bachelor of Business Administration in Accounting from Adelphi University.